Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Hematologic Neoplasms 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Neoplasm, Residual 2Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Anemia, Aplastic 1

Interventions

Dexamethasone 10fludarabine phosphate 9Melphalan 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 7Cyclophosphamide 7Mycophenolic Acid 6Bortezomib 6Tacrolimus 5Calcium Dobesilate 4filanesib 3dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3carfilzomib 3auricularum 3Stem Cell Transplantation 3Sirolimus 3Filgrastim 3liposomal doxorubicin 2ixazomib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × daratumumab × Other hematologic neoplasm × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT05054478 2021-09-23

PCL-2

Assistance Publique - Hôpitaux de Paris

Phase 2 Not yet recruiting
29 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡